Angiotensin II up-regulates expression of inducible nitric oxide synthase in human umbilical endothelial cells: roles of AT1 and AT2.
- Author:
Li-xia YANG
1
;
Rui-wei GUO
;
Yan-kun SHI
;
Feng QI
;
Chuan-ming GUO
;
Ling WEI
;
Yan WANG
Author Information
- Publication Type:Journal Article
- MeSH: Angiotensin II; pharmacology; Angiotensin II Type 1 Receptor Blockers; pharmacology; Angiotensin II Type 2 Receptor Blockers; Cell Line; Endothelial Cells; chemistry; drug effects; Heart Failure; metabolism; Humans; NF-kappa B; metabolism; Nitric Oxide Synthase Type II; biosynthesis; Reverse Transcriptase Polymerase Chain Reaction; Umbilical Veins; cytology; Up-Regulation
- From: Chinese Journal of Cardiology 2006;34(7):647-650
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVEAngiotensin II is an important pro inflammation factor in the cardiovascular system. This experiment is aimed to study the effects of angiotensin II on inducible nitric oxide synthase expression in human umbilical endothelial cells.
METHODSHuman umbilical endothelial cells were cultured in vitro and treated with angiotensin II alone or in combination with AT1, AT2 and NF-kappaB inhibitors respectively. The inducible nitric oxide synthase expressions at protein and mRNA levels were measured with Western blot and reverse transcription-polymerase chain reaction (RT-PCR), and the activity of NF-kappaB was analyzed with EMSA.
RESULTSAngiotensin II up-regulated inducible nitric oxide synthase expressions at the protein and mRNA levels at 5 h (P < 0.05), the activity of NF-kappaB was enhanced at 2 h (P < 0.05). These effects could be blocked by AT1 and NF-kappaB inhibitors but not by AT2 inhibitor.
CONCLUSIONAngiotensin II can upregulate the expression of inducible nitric oxide synthase through NF-kappaB pathway in human umbilical endothelial cells. AT1, other than AT2, play a key role in this process.
